In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

Debates over AI antibody design terminology have clouded the industry’s shared mission of bringing better therapeutics to the ...

According to brokerage Jefferies, the average drug development cycle spans 8 to 10 years, with success rates below 10% and ...

AI-generated Trump video dupes people, India’s first AI blood test, new features for shopping, weather forecasting, reducing ...

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

Artificial intelligence and robotics are revolutionizing drug discovery by automating laboratory processes and enabling rapid ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Every healthcare company claims to be working in the patient's best interest, and yet prices only seem to rise.

Technical decisions that advance inference capabilities can help deliver the promise of ubiquitous, accessible AI.

The internet freaked out after Anthropic revealed that Claude attempts to report “immoral” activity to authorities under ...

Cornell researchers are demonstrating how artificial intelligence—particularly deep learning and generative modeling—can ...

a generative AI model capable of generating realistic 3D structures of small molecules that can serve as promising drug candidates. The study is published in Nature Machine Intelligence.